Halozyme Therapeutics (HALO) Tops Q4 EPS by 2c ; Offers Guidance
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $72.64 +2.09%
EPS Growth %: +17.5%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +17.5%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.82, $0.02 better than the analyst estimate of $0.80. Revenue for the quarter came in at $230 million versus the consensus estimate of $232 million.
GUIDANCE:
Halozyme Therapeutics sees FY2024 EPS of $3.55-$3.90, versus the consensus of $3.64. Halozyme Therapeutics sees FY2024 revenue of $915-985 million, versus the consensus of $961.1 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Outdoor Brands (AOUT) Tops Q4 EPS by 14c
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
- Acuity Brands (AYI) Tops Q3 EPS by 15c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
